The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...

Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by ...

Shares of Bio-Techne Corp. shed 3.71% to $71.83 Wednesday, on what proved to be an all-around dismal trading session for the ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Amgen (NASDAQ:AMGN – Free Report) had its price target decreased by Citigroup from $310.00 to $295.00 in a research report released on Tuesday morning,Benzinga reports. Citigroup currently has a ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a ...

Amgen’s Blincyto (blinatumomab) has been approved by the European Commission (EC) to treat certain acute lymphoblastic ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...